丽珠医药

1513.HK

Wind Industry: 医疗保健 > 医药生物 > 制药 > 西药

公司是集医药研发、生产、销售为一体的综合性企业集团，A+H股上市公司。本集团持续关注全球新药研发领域新分子和前沿技术，基于临床价值、差异化前瞻布局创新药及高壁垒复杂制剂，聚焦消化道、神经精神、辅助生殖、抗肿瘤等领域。进一步健全了研发创新体系，优化了临床管理医学、运营相关部门的管理架构，全面覆盖医学研究、临床运营、药物警戒等多维度管理，在研化学药重点项目取得了阶段性进展，形成了完善的产品集群以及覆盖研发全周期的差异化产品管线。未来，丽珠将继续坚守“患者生命质量第一”的使命和“做医药行业领先者”的愿景，专注生命健康领域，持续以患者临床需求为导向，通过数字化、智能化的技术模式加速提升研发效率，进一步强化在创新药与高壁垒复杂制剂平台上的领先优势，全面提升可持续发展能力。同时将积极响应国家政策号召，持续肩负药企担当，为健康中国作出更多贡献。

ESG Score Industry Ranking:
10 / 282 (制药)

ESG Rating Distribution(制药)

0.35%

AAA

2.84%

17.73%

20.21%

BBB

30.14%

24.11%

0.35%

CCC

Trend of Rating

About Wind ESG Rating

Wind has developed a rigorous rating methodology based on the core connotations of ESG, aligning with international standards and frameworks, and incorporating the characteristics of Chinese companies, to assess the company's essential ESG performance, risk and its ability to operate sustainably.

Focusing on the ESG risks and opportunities of each industry, the companies are rated on a AAA-CCC scale relative to the performance of their industry peers. Wind ESG rating is updated annually or in response to major changes.

The Wind ESG Rating Issuer Communication Platform (esg.wind.com.cn) is now available. Rated companies can access their detailed rating information through this platform, and communicate with or provide feedback to the Wind ESG Rating team regarding specific rating components. For any additional questions, please feel free to send an email to GR.ESG@wind.com.cn.

ESG Score

ESG Score：7.94Updated on 2026-10-29

07.9410

Management & Practices Score：4.94Updated on 2026-09-29

04.947

Controversies Score：2.99Updated on 2026-10-29

02.993

ESG Score Comparison

Indicator	Company Score	Industry Average	Weight
Environmental	5.51	3.56	22.85%
Social	7.94	3.72	49.76%
Governance	6.76	5.34	27.39%

Wind ESG Rating Framework

Building on the foundation of domestic and international ESG policies and standards, our proprietary ESG rating framework considers the development of Chinese capital market and integrates the characteristics of the Chinese companies in various industries. The Wind ESG Rating framework is composed of management & practice and controversies assessment, including:

500+ management & practices indicators, covering E, S and G pillars, reflecting long-term ESG fundamental impacts
1,200+ risk labels, covering news, regulatory penalties and lawsuits, reflecting impact of short-term risks

Management & practice score is the weighted summation of E, S and G pillar scores. The weights reflect both the relative impact of each issue within each industry and the negative or positive contribution of each industry to the environment and society relative to other industries.

Controversies score and ESG score are updated daily, E, S and G pillar scores and management & practice score are updated with underlying data, corresponding data are released on various channels, including Wind Financial Terminal.

Explore More

Wind ESG Rating Methodology.pdf1,198KB Wind ESG Ratings FAQs.pdf755KB

More Details

Peer Comparison(282 companies in the industry) ?

Ranking	Code	Security Name	ESG Rating	ESG Score	Controversies Score	Management & Practices Score	Environmental	Social	Governance
1	600535.SH	天士力	AAA	8.94	3.00	5.94	9.07	8.63	7.75
2	301130.SZ	西点药业	AA	8.39	3.00	5.39	7.28	7.78	7.92
3	3320.HK	华润医药	AA	8.31	3.00	5.31	7.23	7.73	7.62
4	600380.SH	健康元	AA	8.22	3.00	5.22	5.64	8.16	7.66
5	603896.SH	寿仙谷	AA	8.18	3.00	5.18	6.54	7.51	7.92
6	600329.SH	达仁堂	AA	8.15	3.00	5.15	6.24	7.44	8.16
7	2607.HK	上海医药	AA	8.07	3.00	5.07	7.19	7.17	7.40
8	000999.SZ	华润三九	AA	8.03	3.00	5.03	7.66	7.39	6.42
9	301281.SZ	科源制药	A	7.99	2.99	4.99	5.58	7.51	7.72
10	1513.HK	丽珠医药	AA	7.94	2.99	4.94	5.51	7.94	6.76